Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial

被引：0

作者：

Mullin, Kathleen ^{[1
]}

Croop, Robert ^{[2
]}

Pavlovic, Jelena M. ^{[3
]}

Mosher, Linda ^{[2
]}

Smith, Timothy R. ^{[4
]}

Madonia, Jennifer ^{[2
]}

Lovegren, Meghan ^{[2
]}

Coric, Vladimir ^{[2
]}

Lipton, Richard B. ^{[3
]}

机构：

[1] New England Inst Neurol & Headache, Stamford, CT USA

[2] Biohaven Pharmaceut, New Haven, CT USA

[3] Albert Einstein Coll Med, Bronx, NY USA

[4] StudyMetrix Res, St Louis, MO USA

来源：

CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

MTIS22-LBA

引用

页码：126 / 127

页数：2

共 50 条

[1] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
Mullin, K.
Croop, R.
Pavlovic, J.
Mosher, L.
Smith, T.
Madonia, J.
Lovegren, M.
Coric, V.
Lipton, R.
[J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[2] Efficacy and safety of zavegepant nasal spray for the acute treatment of migraine: Results of a phase 3 double-blind, randomized, placebo controlled trial
Mullin, K.
Croop, R.
Pavlovic, J. M.
Mosher, L.
Smith, T. R.
Madonia, J.
Lovegren, M.
Coric, V
Lipton, R. B.
[J]. HEADACHE, 2022, 62 : 128 - 129
[3] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
Mullin, Kathleen
Croop, Robert
Pavlovic, Jelena
Mosher, Linda
Smith, Timothy
Madonia, Jennifer
Lovegren, Meghan
Lipton, Richard
[J]. NEUROLOGY, 2023, 100 (17)
[4] Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial
Croop, Robert
Madonia, Jennifer
Stock, David A.
Thiry, Alexandra
Forshaw, Micaela
Murphy, Abigail
Coric, Vladimir
Lipton, Richard B.
[J]. HEADACHE, 2022, 62 (09): : 1153 - 1163
[5] Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA : a phase 3, double-blind, randomised, placebo-controlled multicentre trial
Lipton, Richard B.
Croop, Robert
Stock, David A.
Madonia, Jennifer
Forshaw, Micaela
Lovegren, Meghan
Mosher, Linda
Coric, Vladimir
Goadsby, Peter J.
[J]. LANCET NEUROLOGY, 2023, 22 (03):
[6] Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial (vol 22, pg 209, 2023)
Lipton, R. B.
Croop, R.
Stock, D. A.
[J]. LANCET NEUROLOGY, 2023, 22 (05): : e7 - e7
[7] A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents
Winner, P
Rothner, AD
Saper, J
Nett, R
Asgharnejad, M
Laurenza, A
Austin, R
Peykamian, M
[J]. PEDIATRICS, 2000, 106 (05) : 989 - 997
[8] Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial
Silberstein, Stephen D.
Lipton, Richard B.
Dodick, David W.
Freitag, Frederick G.
Ramadan, Nabih
Mathew, Ninan
Brandes, Jan L.
Bigal, Marcelo
Saper, Joel
Ascher, Steven
Jordan, Donna M.
Greenberg, Steven J.
Hulihan, Joseph
[J]. HEADACHE, 2007, 47 (02): : 170 - 180
[9] Efficacy and safety of STS101 DHE nasal powder for the acute treatment of migraine: Results from the Phase 3 double-blind, randomized, placebo-controlled SUMMIT study
Lipton, R.
Tepper, S.
Albrecht, D.
[J]. HEADACHE, 2023, 63 : 112 - 113
[10] A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
Voss, Tiffini
Lipton, Richard B.
Dodick, David W.
Dupre, Nicole
Ge, Joy Yang
Bachman, Robert
Assaid, Christopher
Aurora, Sheena K.
Michelson, David
[J]. CEPHALALGIA, 2016, 36 (09) : 887 - 898

← 1 2 3 4 5 →